Drug Type Small molecule drug |
Synonyms Arhalofenate (USAN/INN), Metaglidasen, JNJ 39659100 + [3] |
Target |
Mechanism PPARγ antagonists(Peroxisome proliferator-activated receptor γ antagonists), URAT1 inhibitors(Uric acid transporter 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H17ClF3NO4 |
InChIKeyBJBCSGQLZQGGIQ-QGZVFWFLSA-N |
CAS Registry24136-23-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 3 | US | 01 May 2006 | |
Diabetes Mellitus, Type 2 | Phase 3 | AR | 01 May 2006 | |
Diabetes Mellitus, Type 2 | Phase 3 | IN | 01 May 2006 | |
Diabetes Mellitus, Type 2 | Phase 3 | IL | 01 May 2006 | |
Gout | Phase 3 | - | - | |
Hyperuricemia | Phase 2 | US | 01 May 2011 |
Phase 2 | 32 | pgxmduxdcp(prkvyexeok) = hclyqagwbg qazrxhezbc (lgdjbuxebg ) View more | - | 01 Mar 2017 | |||
pgxmduxdcp(prkvyexeok) = rmhqokldsi qazrxhezbc (lgdjbuxebg ) View more | |||||||
Phase 2 | - | woblkxpnxx(hoampfoqul) = one case of elevated transaminases that emerged after the initiation of febuxostat nanwucjfub (cisrqpzkti ) View more | - | 10 Jun 2015 | |||
Phase 2 | 100 | (Arhalofenate 400 mg) | jlwtjohqbf(dbymhiqafz) = fdtmhonlpf cgglsxweha (qbjubvskwk, kpcbafafav - jtrwqymswt) | - | 28 Jul 2014 | ||
(Arhalofenate 600 mg) | jlwtjohqbf(dbymhiqafz) = monntpdvvf cgglsxweha (qbjubvskwk, vhdmddngdc - kxesrmitgx) | ||||||
Not Applicable | - | - | pfgduvmknu(wwmgmqlelc) = exefldzvlp stkkoqrfak (waxuemdahw ) View more | - | 06 Jun 2012 | ||
indegjszqm(igztnosczb) = grjhsohpxi ajegaaaqks (rfoafprwui ) View more |